G M Cole

Summary

Affiliation: University of California
Country: USA

Publications

  1. pmc What was lost in translation in the DHA trial is whom you should intend to treat
    Sally A Frautschy
    Veterans Greater Los Angeles Healthcare System, Geriatric Research Education and Clinical Center, 16111 Plummer St, North Hills, CA 91343, USA
    Alzheimers Res Ther 3:2. 2011
  2. ncbi request reprint NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models
    Greg M Cole
    Greater Los Angeles Healthcare System, Veterans Administration Medical Center, North Hills, CA 91343, USA
    Ann N Y Acad Sci 1035:68-84. 2004
  3. ncbi request reprint Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education and Clinical Center, California, USA
    Nutr Health 18:249-59. 2006
  4. pmc Neuroprotective effects of curcumin
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education, and Clinic Center, Sepulveda, CA 91343, USA
    Adv Exp Med Biol 595:197-212. 2007
  5. ncbi request reprint Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education and Clinical Center, Sepulveda, CA 91343, USA
    Neurobiol Aging 26:133-6. 2005
  6. doi request reprint Omega-3 fatty acids and dementia
    Greg M Cole
    Department of Medicine at University of California, Los Angeles, CA, USA
    Prostaglandins Leukot Essent Fatty Acids 81:213-21. 2009
  7. ncbi request reprint The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education and Clinical Center, 16111 Plummer Street, Sepulveda, CA 91343, USA
    Exp Gerontol 42:10-21. 2007
  8. ncbi request reprint Alzheimer's amyloid story finds its star
    Greg M Cole
    Department of Medicine and Neurology, UCLA SFVP and GLAVA GRECC 11E, 16111 Plummer, North Hills, CA 91343, USA
    Trends Mol Med 12:395-6. 2006
  9. ncbi request reprint Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein
    G M Cole
    Sepulveda VA Medical Center, Sepulveda, California 91343, USA
    Microsc Res Tech 50:316-24. 2000
  10. doi request reprint Dietary fatty acids and the aging brain
    Greg M Cole
    Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Nutr Rev 68:S102-11. 2010

Research Grants

Collaborators

Detail Information

Publications62

  1. pmc What was lost in translation in the DHA trial is whom you should intend to treat
    Sally A Frautschy
    Veterans Greater Los Angeles Healthcare System, Geriatric Research Education and Clinical Center, 16111 Plummer St, North Hills, CA 91343, USA
    Alzheimers Res Ther 3:2. 2011
    ..should preclinical and clinical studies be performed to optimize dose and mitigate oxidation before pursuing intervention or prevention trials with DHA? And finally, should DHA be tested now for mild cognitive impairment or prevention?..
  2. ncbi request reprint NSAID and antioxidant prevention of Alzheimer's disease: lessons from in vitro and animal models
    Greg M Cole
    Greater Los Angeles Healthcare System, Veterans Administration Medical Center, North Hills, CA 91343, USA
    Ann N Y Acad Sci 1035:68-84. 2004
    ..Curcumin directly targeted Abeta and was also effective in other models, warranting further preclinical and clinical exploration...
  3. ncbi request reprint Docosahexaenoic acid protects from amyloid and dendritic pathology in an Alzheimer's disease mouse model
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education and Clinical Center, California, USA
    Nutr Health 18:249-59. 2006
    ..Many Western diets are typically deficient in DHA and low in polyphenolic antioxidant intake. These and other data argue that increasing dietary intake of both DHA and polyphenolic antioxidants may be useful for AD prevention...
  4. pmc Neuroprotective effects of curcumin
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education, and Clinic Center, Sepulveda, CA 91343, USA
    Adv Exp Med Biol 595:197-212. 2007
    ..Promising results have already led to ongoing pilot clinical trials...
  5. ncbi request reprint Prevention of Alzheimer's disease: Omega-3 fatty acid and phenolic anti-oxidant interventions
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education and Clinical Center, Sepulveda, CA 91343, USA
    Neurobiol Aging 26:133-6. 2005
    ..Both DHA and curcumin have favorable safety profiles, epidemiology and efficacy, and may exert general anti-aging benefits (anti-cancer and cardioprotective.)...
  6. doi request reprint Omega-3 fatty acids and dementia
    Greg M Cole
    Department of Medicine at University of California, Los Angeles, CA, USA
    Prostaglandins Leukot Essent Fatty Acids 81:213-21. 2009
    ..Clinical trials are underway to prevent and treat AD. Results to-date suggest that DHA may be more effective if it is begun early or used in conjunction with antioxidants...
  7. ncbi request reprint The role of insulin and neurotrophic factor signaling in brain aging and Alzheimer's Disease
    Greg M Cole
    Greater Los Angeles Veterans Affairs Healthcare System, Geriatric Research, Education and Clinical Center, 16111 Plummer Street, Sepulveda, CA 91343, USA
    Exp Gerontol 42:10-21. 2007
    ..A better understanding of the precise mechanisms underlying alterations in the insulin/neurotrophic factor signal transduction pathways should aid the search for better AD therapeutic and prevention strategies...
  8. ncbi request reprint Alzheimer's amyloid story finds its star
    Greg M Cole
    Department of Medicine and Neurology, UCLA SFVP and GLAVA GRECC 11E, 16111 Plummer, North Hills, CA 91343, USA
    Trends Mol Med 12:395-6. 2006
    ..These authors used a transgenic mouse model to identify a specific type of aggregate that emerges with cognitive deficits and is capable of transmitting a spatial memory defect to unimpaired animals...
  9. ncbi request reprint Influence of lipoproteins on microglial degradation of Alzheimer's amyloid beta-protein
    G M Cole
    Sepulveda VA Medical Center, Sepulveda, California 91343, USA
    Microsc Res Tech 50:316-24. 2000
    ....
  10. doi request reprint Dietary fatty acids and the aging brain
    Greg M Cole
    Department of Medicine, University of California, Los Angeles, Los Angeles, California, USA
    Nutr Rev 68:S102-11. 2010
    ..Evidence presented here shows DHA acts to oppose this, exerting a plethora of pleiotropic activities to protect against the pathogenesis of Alzheimer's disease...
  11. pmc DHA may prevent age-related dementia
    Greg M Cole
    Departments of Medicine and Neurology, University of California, Los Angeles, CA 90095, USA
    J Nutr 140:869-74. 2010
    ..We advocate early intervention in a prodromal period with nutrigenomically defined subjects with an appropriately designed nutritional supplement, including DHA and antioxidants...
  12. ncbi request reprint Lipoprotein effects on Abeta accumulation and degradation by microglia in vitro
    G M Cole
    Sepulveda VAMC, GRECC, and Departments of Medicine and Neurology, University of California Los Angeles, Sepulveda 91343, USA
    J Neurosci Res 57:504-20. 1999
    ..These data suggest that lipoprotein-dependent Abeta trafficking to microglia could be relevant to plaque pathogenesis in AD...
  13. ncbi request reprint Phenolic anti-inflammatory antioxidant reversal of Abeta-induced cognitive deficits and neuropathology
    S A Frautschy
    VAGLAHS Sepulveda GRECC, Departments of Medicine and Neurology, UCLA, 16111 Plummer Street, North Hills, CA, USA
    Neurobiol Aging 22:993-1005. 2001
    ..Because of its low side-effect profile and long history of safe use, curcumin may find clinical application for AD prevention...
  14. ncbi request reprint Binding characteristics of radiofluorinated 6-dialkylamino-2-naphthylethylidene derivatives as positron emission tomography imaging probes for beta-amyloid plaques in Alzheimer's disease
    E D Agdeppa
    Division of Nuclear Medicine, Department of Molecular and Medical Pharmacology, Laboratory of Structural Biology and Molecular Medicine, University of California Los Angeles School of Medicine, Los Angeles, California 90095, USA
    J Neurosci 21:RC189. 2001
    ....
  15. ncbi request reprint Ibuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice
    G P Lim
    VAGLAHS-Sepulveda GRECC, Departments of Medicine and Neurology, UCLA, Los Angeles, CA, USA
    Neurobiol Aging 22:983-91. 2001
    ..05). Although interleukin-1beta and insoluble Abeta were more effectively reduced with longer treatment, the magnitude of the effect on soluble Abeta was not dependent on treatment duration...
  16. ncbi request reprint Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
    G P Lim
    University of California Los Angeles, Departments of Medicine and Neurology, 90095, USA
    J Neurosci 20:5709-14. 2000
    ....
  17. ncbi request reprint The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse
    G P Lim
    Departments of Medicine and Neurology, University of California, Los Angeles, Los Angeles, California 90095, USA
    J Neurosci 21:8370-7. 2001
    ..Microgliosis was also suppressed in neuronal layers but not adjacent to plaques. In view of its efficacy and apparent low toxicity, this Indian spice component shows promise for the prevention of Alzheimer's disease...
  18. doi request reprint Beta-amyloid oligomers induce phosphorylation of tau and inactivation of insulin receptor substrate via c-Jun N-terminal kinase signaling: suppression by omega-3 fatty acids and curcumin
    Qiu Lan Ma
    Department of Medicine, University of California, Los Angeles, Los Angeles, California 90095, USA
    J Neurosci 29:9078-89. 2009
    ....
  19. ncbi request reprint A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model
    Giselle P Lim
    Department of Medicine, University of California Los Angeles, Los Angeles, California 90095, USA
    J Neurosci 25:3032-40. 2005
    ..Together, these results suggest that dietary DHA could be protective against beta-amyloid production, accumulation, and potential downstream toxicity...
  20. pmc Antibody to caspase-cleaved actin detects apoptosis in differentiated neuroblastoma and plaque-associated neurons and microglia in Alzheimer's disease
    F Yang
    Department of Medicine and Neurology, UCLA, Los Angeles, California, USA
    Am J Pathol 152:379-89. 1998
    ..In situ detection of caspase-cleaved actin provides a new means to evaluate the role of caspase activation in pathological and physiological processes...
  21. ncbi request reprint Defective neuronal sprouting by human apolipoprotein E4 is a gain-of-negative function
    B Teter
    Veterans Administration Greater Los Angeles Healthcare System and Department of Medicine, University of California, Los Angeles, Sepulveda, California 91343, USA
    J Neurosci Res 68:331-6. 2002
    ..These results may have important pharmacogenomic implications for AD therapies that modulate apoE expression levels...
  22. ncbi request reprint Selective inhibition of Abeta42 production by NSAID R-enantiomers
    T Morihara
    Department of Medicine, University of California, Los Angeles, California, USA
    J Neurochem 83:1009-12. 2002
    ..Because of its efficacy at lowering Abeta42 production and low toxicity profile, R-flurbiprofen is a strong candidate for clinical development...
  23. ncbi request reprint Estrogen (E2) and glucocorticoid (Gc) effects on microglia and A beta clearance in vitro and in vivo
    M E Harris-White
    Department of Medicine, UCLA, C-128 RNRC, Los Angeles, CA 90095-1769, USA
    Neurochem Int 39:435-48. 2001
    ..The failure of both steroids to accelerate A beta degradation may explain their lack of efficacy for treatment of AD...
  24. ncbi request reprint Cat and mouse
    Greg M Cole
    Greater Los Angeles Healthcare System, Veterans Administration Medical Center, Geriatric Research Education Clinical Center, North Hills, California 91343, USA
    Neuron 51:671-2. 2006
    ..manipulate the expression of cathepsin B in aged APP transgenic mice, observing that increased expression degrades preformed oligomeric and fibrillar amyloid, while inactivation accelerates beta-amyloidosis...
  25. ncbi request reprint Antibodies against beta-amyloid reduce Abeta oligomers, glycogen synthase kinase-3beta activation and tau phosphorylation in vivo and in vitro
    Qiu Lan Ma
    Department of Medicine, University of California, Los Angeles, California 91343, USA
    J Neurosci Res 83:374-84. 2006
    ..These data suggest that antibodies that are highly specific for toxic oligomer subspecies may reduce toxicity via reduction of GSK-3beta, which could be an important strategy for Alzheimer's disease (AD) therapeutics...
  26. pmc Reduction of SorLA/LR11, a sorting protein limiting beta-amyloid production, in Alzheimer disease cerebrospinal fluid
    Qiu Lan Ma
    Department of Medicine, University of California, Los Angeles, California, USA
    Arch Neurol 66:448-57. 2009
    ..LR11 protein is reduced in patients with late-onset AD, and LR11 polymorphisms have been associated with late-onset AD...
  27. ncbi request reprint In vitro detection of (S)-naproxen and ibuprofen binding to plaques in the Alzheimer's brain using the positron emission tomography molecular imaging probe 2-(1-[6-[(2-[(18)F]fluoroethyl)(methyl)amino]-2-naphthyl]ethylidene)malononitrile
    E D Agdeppa
    Division of Nuclear Medicine, Department of Molecular and Medical Pharmacology, Laboratory of Structural Biology and Molecular Medicine, The David Geffen School of Medicine at UCLA, Box 956948, Los Angeles, CA 90095, USA
    Neuroscience 117:723-30. 2003
    ....
  28. ncbi request reprint Dietary n-3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease
    Frederic Calon
    Department of Medicine, University of California, Los Angeles, California, USA
    Eur J Neurosci 22:617-26. 2005
    ..The marked effect of dietary n-3 PFA on NMDA receptors and caspase/calpain activation in the cortex of an animal model of AD provide new insights into how dietary essential fatty acids may influence cognition and AD risk...
  29. doi request reprint Biochemical markers in persons with preclinical familial Alzheimer disease
    J M Ringman
    UCLA Department of Neurology, Alzheimer Disease Research Center, 10911 Weyburn Ave, Suite 200, Los Angeles, CA 90095 7226, USA
    Neurology 71:85-92. 2008
    ..Persons at risk for familial Alzheimer disease (FAD) provide a model in which biomarkers can be studied in presymptomatic disease...
  30. ncbi request reprint Quantitative characterization of crude synaptosomal fraction (P-2) components by flow cytometry
    K H Gylys
    UCLA School of Nursing, Los Angeles, California 90095 6919, USA
    J Neurosci Res 61:186-92. 2000
    ..These results suggest that flow cytometry may be used to take advantage of the increased viability, yield, and convenience of the P-2 fraction for studies of nerve terminal function...
  31. pmc Current and future uses of neuroimaging for cognitively impaired patients
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and Semel Institute for Neuroscience and Human Behavior, University of California Los Angeles, Los Angeles, California, USA
    Lancet Neurol 7:161-72. 2008
    ....
  32. ncbi request reprint Use of copper and insulin-resistance to accelerate cognitive deficits and synaptic protein loss in a rat Abeta-infusion Alzheimer's disease model
    Aynun N Begum
    Department of Medicine, University of California, Los Angeles, CA, USA
    J Alzheimers Dis 15:625-40. 2008
    ..In summary, the newly described in vivo infusion model may be useful cost-effective method for screening for new therapeutic drugs for AD...
  33. doi request reprint GSK3 inhibitors show benefits in an Alzheimer's disease (AD) model of neurodegeneration but adverse effects in control animals
    Shuxin Hu
    Greater Los Angeles Healthcare System, Geriatric Research Education and Clinical Center, Veteran s Affairs Medical Center, USA
    Neurobiol Dis 33:193-206. 2009
    ..These data support a role for GSK3 hyperactivation in AD pathogenesis, but emphasize the importance of developing inhibitors that do not suppress constitutive activity...
  34. ncbi request reprint Cell type specific targeted intracellular delivery into muscle of a monoclonal antibody that binds myosin IIb
    Richard H Weisbart
    Department of Medicine, Division of Rheumatology, Veterans Affairs Greater Los Angeles Health Care System, Sepulveda, CA 91343, USA
    Mol Immunol 39:783-9. 2003
    ..Myosin IIb is implicated in the specific targeting of mAb 3E10 to skeletal muscle...
  35. ncbi request reprint PET of brain amyloid and tau in mild cognitive impairment
    Gary W Small
    Department of Psychiatry and Biobehavioral Sciences and the Semel Institute for Neuroscience and Human Behavior, David Geffen School of Medicine at the University of California, Los Angeles, USA
    N Engl J Med 355:2652-63. 2006
    ..Noninvasive methods to detect these abnormal proteins are potentially useful in developing surrogate markers for drug discovery and diagnostics...
  36. pmc Omega-3 fatty acid docosahexaenoic acid increases SorLA/LR11, a sorting protein with reduced expression in sporadic Alzheimer's disease (AD): relevance to AD prevention
    Qiu Lan Ma
    Department of Medicine, University of California, Los Angeles, California 90095, USA
    J Neurosci 27:14299-307. 2007
    ..Because reduced LR11 is known to increase Abeta production and may be a significant genetic cause of LOAD, our results indicate that DHA increases in SorLA/LR11 levels may play an important role in preventing LOAD...
  37. ncbi request reprint Role of p21-activated kinase pathway defects in the cognitive deficits of Alzheimer disease
    Lixia Zhao
    Greater Los Angeles Veterans Affairs Healthcare System, Sepulveda, California 91343, USA
    Nat Neurosci 9:234-42. 2006
    ....
  38. pmc Influence of cognitive status, age, and APOE-4 genetic risk on brain FDDNP positron-emission tomography imaging in persons without dementia
    Gary W Small
    Semel Institute, 760 Westwood Plaza, Ste 88 201, Los Angeles, CA 90024, USA
    Arch Gen Psychiatry 66:81-7. 2009
    ..Here we investigated whether known risk factors for Alzheimer disease and dementia are associated with FDDNP-PET binding...
  39. pmc Why pleiotropic interventions are needed for Alzheimer's disease
    Sally A Frautschy
    Geriatric Research and Clinical Center, Greater Los Angeles Healthcare System, Veteran s Administration, Los Angeles, USA
    Mol Neurobiol 41:392-409. 2010
    ....
  40. pmc Docosahexaenoic acid protects from dendritic pathology in an Alzheimer's disease mouse model
    Frederic Calon
    Department of Medicine, University of California, Los Angeles, 90095, USA
    Neuron 43:633-45. 2004
    ..Since n-3 PFAs are essential for p85-mediated CNS insulin signaling and selective protection of postsynaptic proteins, these findings have implications for neurodegenerative diseases where synaptic loss is critical, especially AD...
  41. ncbi request reprint Antibody-mediated transduction of p53 selectively kills cancer cells
    Richard H Weisbart
    Division of Rheumatology, Department of Medicine, Veterans Affairs Greater Los Angeles Health Care System, Sepulveda, CA 91343, USA
    Int J Oncol 25:1867-73. 2004
    ..Fv-p53 was shown to penetrate cancer cells engrafted in vivo. These results support continued efforts to evaluate the potential efficacy of Fv-p53 for the treatment of certain cancers in vivo...
  42. ncbi request reprint Apoptosis in a neonatal rat model of cerebral hypoxia-ischemia
    M R Pulera
    Department of Neurology, Veteran s Affairs Medical Center, Sepulveda, Calif, USA
    Stroke 29:2622-30. 1998
    ..BACKGROUND and..
  43. ncbi request reprint Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention
    Lixia Zhao
    Department of Medicine, University of California Los Angeles, California 91343, USA
    J Neurosci 24:11120-6. 2004
    ..These in vitro and in vivo analyses validate the use of enhanced CNS insulin signaling as a potential strategy for AD intervention to correct the IDE defects occurring in AD...
  44. pmc Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease
    Aynun N Begum
    Department of Medicine, University of California, Los Angeles, California, USA
    J Pharmacol Exp Ther 326:196-208. 2008
    ....
  45. ncbi request reprint Ibuprofen suppresses interleukin-1beta induction of pro-amyloidogenic alpha1-antichymotrypsin to ameliorate beta-amyloid (Abeta) pathology in Alzheimer's models
    Takashi Morihara
    Greater Los Angeles VA Healthcare System, GRECC, Sepulveda, CA, USA
    Neuropsychopharmacology 30:1111-20. 2005
    ..We present evidence supporting the hypothesis that ibuprofen-dependent amyloid reduction is mediated by inhibition of an alternate pathway (IL-1beta and its downstream target ACT)...
  46. ncbi request reprint Mechanisms of action of non-steroidal anti-inflammatory drugs for the prevention of Alzheimer's disease
    Greg M Cole
    Geriatric Research and Education Center, North Hills, CA 91343, USA
    CNS Neurol Disord Drug Targets 9:140-8. 2010
    ..This encourages researchers to re-address possible mechanisms for a stage-dependent NSAID efficacy, the subject of this review...
  47. pmc Evidence of Abeta- and transgene-dependent defects in ERK-CREB signaling in Alzheimer's models
    Qiu Lan Ma
    Department of Medicine, University of California, Los Angeles, California, USA
    J Neurochem 103:1594-607. 2007
    ..These effects were reversed by anti-oligomer. Our data strongly support the existence of an APPsw transgene-dependent and Abeta oligomer-mediated defect in regulation of ERK activation...
  48. pmc p21-activated kinase-aberrant activation and translocation in Alzheimer disease pathogenesis
    Qiu Lan Ma
    Department of Medicine, UCLA, Los Angeles, California, USA
    J Biol Chem 283:14132-43. 2008
    ..Our results implicate aberrant PAK in Abeta oligomer-induced signaling and synaptic deficits in Alzheimer disease...
  49. ncbi request reprint Ironic fate: can a banned drug control metal heavies in neurodegenerative diseases?
    Greg M Cole
    Greater Los Angeles VA Medical Center, UCLA Alzheimer s Disease Research Center, Sepulveda, CA 91343, USA
    Neuron 37:889-90. 2003
    ..This raises the issue of specific iron chelators or clioquinol for control of oxidative damage in Parkinson's, Alzheimer's, and other neurodegenerative diseases, but not without safety concerns...
  50. ncbi request reprint Role of apolipoprotein E and estrogen in mossy fiber sprouting in hippocampal slice cultures
    B Teter
    Greater Los Angeles Veteran s Healthcare System, Sepulveda, and Department of Medicine, University of California, Los Angeles, 91343, USA
    Neuroscience 91:1009-16. 1999
    ..Estrogen and apolipoprotein E may therefore interact in their modulation of both Alzheimer's disease risk and recovery from CNS injury...
  51. ncbi request reprint Caspase inhibition protects nerve terminals from in vitro degradation
    Karen H Gylys
    UCLA School of Nursing, Brain Research Institute, Box 956919, Los Angeles, California 90095, USA
    Neurochem Res 27:465-72. 2002
    ..These results indicate activation of both caspase and calpain in the P-2 fraction and suggest a role for these cysteine proteases in the in vitro degradation of nerve terminals...
  52. ncbi request reprint Enrichment of presynaptic and postsynaptic markers by size-based gating analysis of synaptosome preparations from rat and human cortex
    Karen H Gylys
    UCLA School of Nursing and Brain Research Institute, UCLA School of Medicine, Los Angeles, California 90095, USA
    Cytometry A 60:90-6. 2004
    ....
  53. ncbi request reprint Increased cholesterol in Abeta-positive nerve terminals from Alzheimer's disease cortex
    Karen Hoppens Gylys
    UCLA School of Nursing, Los Angeles, CA 90095, USA
    Neurobiol Aging 28:8-17. 2007
    ..These results suggest that Abeta accumulation in synaptic terminals may underly dysfunction prior to or independent of extracellular amyloid deposition...
  54. ncbi request reprint Rapid annexin-V labeling in synaptosomes
    Karen H Gylys
    UCLA School of Nursing and Brain Research Institute, Box 956919, Factor Building, Los Angeles, CA 90095, USA
    Neurochem Int 44:125-31. 2004
    ..These data demonstrate that PS externalization and caspase activation occur rapidly in this widely used neurochemical preparation...
  55. ncbi request reprint Intracellular Abeta is increased by okadaic acid exposure in transfected neuronal and non-neuronal cell lines
    Xiaoyan Sun
    Laboratory for Alzheimer s Disease, Brain Science Institute of the RIKEN, 2 1 Hirosawa, Wako, 351 0198, Saitama, Japan
    Neurobiol Aging 23:195-203. 2002
    ..The increased full-length APP and decreased APPC99 were also observed. This is the first study to demonstrate that OA treatment significantly increases intracellular Abeta...
  56. pmc A potential role of the curry spice curcumin in Alzheimer's disease
    John M Ringman
    University of California, Los Angeles, Department of Neurology, Alzheimer s Disease Research Center, Los Angeles, CA 90095, USA
    Curr Alzheimer Res 2:131-6. 2005
    ..We are therefore performing a study of curcumin in patients with AD to gather this information in addition to data on the effect of curcumin on biomarkers of AD pathology...
  57. pmc Synaptic changes in Alzheimer's disease: increased amyloid-beta and gliosis in surviving terminals is accompanied by decreased PSD-95 fluorescence
    Karen Hoppens Gylys
    UCLA School of Nursing and Brain Research Institute, Box 956919 Factor Bldg, Los Angeles, CA 90095 6919, USA
    Am J Pathol 165:1809-17. 2004
    ....
  58. ncbi request reprint Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals
    Karen H Gylys
    UCLA School of Nursing and Brain Research Institute, UCLA School of Medicine, Los Angeles, California 90095 6919, USA
    J Neurochem 84:1442-51. 2003
    ..These results suggest that complex formation with apoE enhances internalization of soluble Abeta uptake into terminals...
  59. pmc Co-localization of amyloid beta and tau pathology in Alzheimer's disease synaptosomes
    Jeffrey A Fein
    School of Nursing, University of California at Los Angeles School of Medicine, Sepulveda Veterans Administration Medical Center, Los Angeles, California 90095 6919, USA
    Am J Pathol 172:1683-92. 2008
    ..0001). These results showing overlapping Abeta and tau pathology are consistent with a model in which both synaptic loss and dysfunction are linked to a synaptic amyloid cascade within the synaptic compartment...
  60. ncbi request reprint Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo
    Fusheng Yang
    Department of Medicine, UCLA, Los Angeles, CA 90095, USA
    J Biol Chem 280:5892-901. 2005
    ..These data suggest that low dose curcumin effectively disaggregates Abeta as well as prevents fibril and oligomer formation, supporting the rationale for curcumin use in clinical trials preventing or treating AD...
  61. pmc Serotonin 1A receptors in the living brain of Alzheimer's disease patients
    Vladimir Kepe
    Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, University of California, Los Angeles, CA 90095, USA
    Proc Natl Acad Sci U S A 103:702-7. 2006
    ....
  62. ncbi request reprint The microglial phagocytic role with specific plaque types in the Alzheimer disease brain
    Michael R D'Andrea
    Drug Discovery, Johnson and Johnson Pharmaceutical Research and Development, D404, Spring House, PA 19477, USA
    Neurobiol Aging 25:675-83. 2004
    ..In summary, the data presented suggests that plaque associated microglial activation is typically subsequent to specific amyloid plaque formations in the AD brain...

Research Grants1

  1. NSAID Inhibition of Alzheimer Pathology: Role of DHA
    Gregory M Cole; Fiscal Year: 2010
    ..Understanding dietary fatty acid /Abeta-related PAK complex deficits and downstream synaptic defects will reveal a poorly studied overlap between cognitive deficits in mental retardation syndromes and AD with therapeutic implications. ..